<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02894385</url>
  </required_header>
  <id_info>
    <org_study_id>17721</org_study_id>
    <secondary_id>2016-001069-10</secondary_id>
    <nct_id>NCT02894385</nct_id>
  </id_info>
  <brief_title>Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)</brief_title>
  <official_title>A Phase I, Non-randomized, Open-label, Single-dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of BAY 1841788 (ODM-201) in Male Subjects With Hepatic Impairment, Renal Impairment and Normal Hepatic and Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the potential effect of hepatic or renal impairment on the pharmacokinetics, safety
      and tolerability of BAY 1841788 (ODM-201).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was closed after Part 1 because additional investigation in volunteers with
      moderate renal impairment in Part 2 was not deemed to be ethically or scientifically
      justified.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 13, 2016</start_date>
  <completion_date type="Actual">December 15, 2017</completion_date>
  <primary_completion_date type="Actual">April 10, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve of darolutamide from time zero to 48 hours (AUC(0-48)) in plasma</measure>
    <time_frame>Pre-dose up to 48 h post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum drug concentration (Cmax) of darolutamide in plasma</measure>
    <time_frame>Pre-dose up to 48 h post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of darolutamide's diastereomer ((S,R)-darolutamide) from time zero to 48 hours (AUC(0-48)) in plasma</measure>
    <time_frame>Pre-dose up to 48 h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum drug concentration (Cmax) of darolutamide's diastereomer ((S,R)-darolutamide) in plasma</measure>
    <time_frame>Pre-dose up to 48 h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of darolutamide's diastereomer ((S,S)-darolutamide) from time zero to 48 hours (AUC(0-48)) in plasma</measure>
    <time_frame>Pre-dose up to 48 h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum drug concentration (Cmax) of darolutamide's diastereomer ((S,S)-darolutamide) in plasma</measure>
    <time_frame>Pre-dose up to 48 h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of darolutamide's major metabolite (keto-darolutamide) from time zero to 48 hours (AUC(0-48)) in plasma</measure>
    <time_frame>Pre-dose up to 48 h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum drug concentration (Cmax) of darolutamide's major metabolite (keto-darolutamide) in plasma</measure>
    <time_frame>Pre-dose up to 48 h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with study drug-related treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>From first application of study medication up to 30 days after end of treatment with study medication.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Pharmacokinetics</condition>
  <condition>Hepatic Insufficiency</condition>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Part 1 - Subjects with severe renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with severe renal impairment received a single oral dose of darolutamide 600 mg (2 x 300 mg tablets).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Subjects with moderate hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with moderate hepatic impairment received a single oral dose of darolutamide 600 mg (2 x 300 mg tablets).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects received a single oral dose of darolutamide 600 mg (2 x 300 mg tablets).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1841788</intervention_name>
    <description>600 mg single dose, administered as 2 x 300 mg tablets on Day 00.</description>
    <arm_group_label>Part 1 - Healthy subjects</arm_group_label>
    <arm_group_label>Part 1 - Subjects with moderate hepatic impairment</arm_group_label>
    <arm_group_label>Part 1 - Subjects with severe renal impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All subjects

             -- Male and white subjects between 45 and 79 years of age with a body mass index
             between 18 to 34 kg/m*2 (both inclusive).

          -  Patients with moderate hepatic impairment (Part 1)

             -- Patients with documented liver cirrhosis confirmed by histopathology, e.g.,
             previous liver biopsy, laparoscopy, ultrasound, or fibroscan and with moderate hepatic
             impairment (defined as Child Pugh class B).

          -  Patients with severe renal impairment (Part 1)

             -- Patients with severe renal impairment with an estimated glomerular filtration rate
             15-29 mL/min/1.73 m*2, who are not on dialysis and are not expected to start dialysis
             in the next 3 months (Stage 4).

          -  Healthy subjects

             -- Healthy as determined by the investigator or medically qualified designee based on
             a medical evaluation including medical history, physical examination, laboratory tests
             and cardiac monitoring and with estimated glomerular filtration rate &gt;90 mL/min
             (according to Modified Diet of Renal Disease equation).

          -  Patients with moderate renal impairment (Part 2)

             -- Patients with moderate renal impairment with an estimated glomerular filtration
             rate 30-59 mL/min/1.73 m*2 (Stage 3).

          -  Patients with mild renal impairment (Part 2)

             -- Patients with mild renal impairment with an estimated glomerular filtration rate
             (eGFR) 60-79 mL/min/1.73 m*2 (Stage 2).

          -  Patients with mild hepatic impairment (Part 2)

               -  Patients with documented liver cirrhosis confirmed by histopathology, e.g.,
                  previous liver biopsy, laparoscopy, ultrasound, or fibroscan.

               -  Patients with mild hepatic impairment (defined as Child Pugh class A).

        Exclusion Criteria:

          -  Severe cerebrovascular or cardiac disorders, e.g., myocardial infarction less than 6
             months prior to dosing, congestive heart failure of New York Heart Association (NYHA)
             grade III or IV.

          -  Subjects with percutaneous transluminal coronary angioplasty or coronary artery bypass
             graft less than 6 months prior to study drug administration.

          -  Strong cytochrome P450 (CYP) 3A4 inhibitors or strong CYP3A4 inducers within 28 days
             or 5 drug half-lives (if drug half-life in patients is known), before start of study
             treatment.

          -  Known BCRP (breast cancer resistant protein) and OATP (organic anion-transporting
             polypeptide) substrates not specifically mentioned in the protocol within 28 days or 5
             drug half-lives (if drug half-life in patients is known), before start of study
             treatment.

          -  Smoking more than 20 cigarettes daily.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>LÃ¼beck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe.</description>
  </link>
  <link>
    <url>https://clinicaltrials.bayer.com/</url>
    <description>Click here to find results for studies related to Bayer products.</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 29, 2016</study_first_submitted>
  <study_first_submitted_qc>September 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2016</study_first_posted>
  <last_update_submitted>January 4, 2019</last_update_submitted>
  <last_update_submitted_qc>January 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

